Comparing LENSAR (NASDAQ:LNSR) and Apyx Medical (NASDAQ:APYX)

Apyx Medical (NASDAQ:APYXGet Free Report) and LENSAR (NASDAQ:LNSRGet Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Apyx Medical and LENSAR, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apyx Medical 0 0 2 0 3.00
LENSAR 0 0 1 0 3.00

Apyx Medical presently has a consensus target price of $6.17, suggesting a potential upside of 285.42%. LENSAR has a consensus target price of $8.00, suggesting a potential upside of 84.33%. Given Apyx Medical’s higher probable upside, equities analysts clearly believe Apyx Medical is more favorable than LENSAR.


This table compares Apyx Medical and LENSAR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apyx Medical -45.20% -76.16% -32.98%
LENSAR -27.57% -36.53% -17.67%

Valuation & Earnings

This table compares Apyx Medical and LENSAR’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apyx Medical $52.35 million 1.06 -$18.71 million ($0.66) -2.42
LENSAR $44.50 million 1.11 -$14.38 million ($1.58) -2.75

LENSAR has lower revenue, but higher earnings than Apyx Medical. LENSAR is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 13.1% of Apyx Medical shares are owned by company insiders. Comparatively, 38.5% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Apyx Medical has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.


Apyx Medical beats LENSAR on 7 of the 13 factors compared between the two stocks.

About Apyx Medical

(Get Free Report)

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.


(Get Free Report)

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with's FREE daily email newsletter.